Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate
作者:Vidya Ramdas、Rashmi Talwar、Moloy Banerjee、Advait Arun Joshi、Amit Kumar Das、Deepak Sahebrao Walke、Prashant Borhade、Usha Dhayagude、Rajesh Loriya、Ganesh Gote、Apparao Bommakanti、Aruna Sivaram、Gautam Agarwal、Arnab Goswami、Prashant Nigade、Maneesh Mehta、Vinod Patil、Dipak Modi、Hemant Kumar、Sadanand Mallurwar、Amruta Dash、Falguni Modi、Sandip Kuldharan、Pratima Srivastava、Minakshi Singh、Lakshmi Narasimham、Jayasagar Gundu、Sharad Sharma、Rajender Kumar Kamboj、Venkata P. Palle
DOI:10.1021/acs.jmedchem.9b01562
日期:2019.12.12
The identification of a novel class of potent pan-genotypic NS5A inhibitors with good pharmacokinetic profile suitable for potential use in treating HCV infections is disclosed here. The present series of compounds are with less complex tricyclic central core, identified through a systematic SAR study carried out on biphenyl moiety. The SAR outcome has confirmed the requirement of near planar and linear
本文公开了一种新型强效泛基因型 NS5A 抑制剂的鉴定,该抑制剂具有良好的药代动力学特征,适用于治疗 HCV 感染。本系列化合物具有不太复杂的三环中心核心,通过对联苯部分进行的系统 SAR 研究确定。SAR结果证实了分子接近平面和线性构象的要求,以实现最佳的泛基因型活性。此外,公开了具有取代咪唑的SAR对提高抗病毒活性的作用。新鉴定的化合物12 , 16 , 19 – 21已经显示出理想的药代动力学特征,其中化合物在肝脏中的吸收良好,并在肝脏中保持显着浓度长达 8 小时。此外,与 ledipasvir 和 daclatasvir 相比,化合物20和21已显示出优异的泛基因型抗 HCV 活性。额外的表征和初步安全性评估导致化合物20被鉴定为潜在的临床候选物。